ALPINE IMMUNE SCIENCES INC (ALPN) Stock Price, Quote, News and Overview
NASDAQ:ALPN - Nasdaq - US02083G1004 - Common Stock - Currency: USD
ALPN Quote, Performance and Key Statistics
64.97
+0.01 (+0.02%)
The current stock price of ALPN is 64.97 USD. In the past month the price increased by 0.65%. In the past year, price increased by 583.9%.
ALPN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About ALPN
Company Profile
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 126 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Company Info
ALPINE IMMUNE SCIENCES INC
188 East Blaine St., Suite 200
Seattle WASHINGTON 98102 US
CEO: Mitchell H. Gold
Employees: 126
Company Website: https://www.alpineimmunesciences.com/
Phone: 12067884545
ALPINE IMMUNE SCIENCES INC / ALPN FAQ
What is the stock price of ALPINE IMMUNE SCIENCES INC today?
The current stock price of ALPN is 64.97 USD. The price increased by 0.02% in the last trading session.
What is the ticker symbol for ALPINE IMMUNE SCIENCES INC stock?
The exchange symbol of ALPINE IMMUNE SCIENCES INC is ALPN and it is listed on the Nasdaq exchange.
On which exchange is ALPN stock listed?
ALPN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALPINE IMMUNE SCIENCES INC stock?
15 analysts have analysed ALPN and the average price target is 62.73 USD. This implies a price decrease of -3.45% is expected in the next year compared to the current price of 64.97. Check the ALPINE IMMUNE SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALPINE IMMUNE SCIENCES INC worth?
ALPINE IMMUNE SCIENCES INC (ALPN) has a market capitalization of 4.46B USD. This makes ALPN a Mid Cap stock.
How many employees does ALPINE IMMUNE SCIENCES INC have?
ALPINE IMMUNE SCIENCES INC (ALPN) currently has 126 employees.
What are the support and resistance levels for ALPINE IMMUNE SCIENCES INC (ALPN) stock?
ALPINE IMMUNE SCIENCES INC (ALPN) has a support level at 64.96 and a resistance level at 64.98. Check the full technical report for a detailed analysis of ALPN support and resistance levels.
Is ALPINE IMMUNE SCIENCES INC (ALPN) expected to grow?
The Revenue of ALPINE IMMUNE SCIENCES INC (ALPN) is expected to decline by -56.25% in the next year. Check the estimates tab for more information on the ALPN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALPINE IMMUNE SCIENCES INC (ALPN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALPN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALPN, evaluating the profitability, health, valuation and growth aspects
- ALPINE IMMUNE SCIENCES INC (ALPN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALPINE IMMUNE SCIENCES INC (ALPN) Sales and EPS estimates to see what analysts future expectations are.
- ALPINE IMMUNE SCIENCES INC (ALPN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALPINE IMMUNE SCIENCES INC (ALPN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALPINE IMMUNE SCIENCES INC (ALPN) Stock Chart to make your own analysis
- ALPINE IMMUNE SCIENCES INC (ALPN) Latest news and press-releases to stay up to date.
Does ALPINE IMMUNE SCIENCES INC (ALPN) stock pay dividends?
ALPN does not pay a dividend.
When does ALPINE IMMUNE SCIENCES INC (ALPN) report earnings?
ALPINE IMMUNE SCIENCES INC (ALPN) will report earnings on 2024-08-12, after the market close.
What is the Price/Earnings (PE) ratio of ALPINE IMMUNE SCIENCES INC (ALPN)?
ALPINE IMMUNE SCIENCES INC (ALPN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
ALPN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALPN. When comparing the yearly performance of all stocks, ALPN is one of the better performing stocks in the market, outperforming 99.78% of all stocks.
ALPN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALPN. ALPN has a great financial health rating, but its profitability evaluates not so good.
ALPN Financial Highlights
Over the last trailing twelve months ALPN reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 60.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.86% | ||
| ROE | -11.07% | ||
| Debt/Equity | 0 |
ALPN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to ALPN. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -157.63% and a revenue growth -56.25% for ALPN